ESC 365 - Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk

ESC Premium Access

Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk

Session: Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

Topic: Diabetes and the Heart

Speaker: Professor J. Deanfield (London, GB)

Sponsored by Novo Nordisk A/S

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

53 presentations

3 followers

3 more presentations in this session

New dimensions in cardiovascular risk: exploring the latest cardiovascular outcomes trials in type 2 diabetes

Speaker: Doctor M. Kosiborod (Kansas City, US)

Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction

Speaker: Doctor B. Scirica (Boston, US)

Connecting with the speakers: Questions and Answers

Speaker: Doctor M. Kosiborod (Kansas City, US) Professor J. Deanfield (London, GB) Doctor B. Scirica (Boston, US)

Access the full session

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

Speakers: Professor J. Deanfield, Doctor M. Kosiborod, Doctor B. Scirica, Doctor M. Kosiborod, Professor J. Deanfield...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources